|
| Friday, 21 July 2023, 20:50 HKT/SGT | |
| |
|
|
|
|
| Revenue is expected to rise 85% to 94% year-on-year |
HONG KONG, July 21, 2023 - (ACN Newswire) - July 21, 2023, Peijia Medical Limited ("Peijia Medical" or the "Company", together with its subsidiaries, the "Group", stock code: 9996.HK) announced its certain 2023 unaudited operating statistics of the Group for the six months ended June 30, 2023 ("the first half of 2023") today, the revenue is expected to increase 85.2 to 93.6% year-on-year, to approximately RMB220 million to RMB230 million.
The increase in revenue in the first half of 2023 was primarily attributable to the commercialization of transcatheter aortic valve replacement products (including the first-generation product TaurusOne and the second-generation retrievable product TaurusElite), which has been accelerated, further increasing the Group's market share.
In addition, benefiting by the sales volume of the Group's existing neurointerventional products (including Tethys Intermediate Catheter, SacSpeed Balloon Dilatation Catheter, Jasper Detachable Coil and Syphonet Stent Retriever, etc.) has increased constantly, hence continuously contributing to the revenue growth of the Group.
Meanwhile, the Group's ischemic products (including Fastunnel Delivery Balloon Dilatation Catheter, etc.) whose registration applications were approved by the National Medical Products Administration of the PRC in the second quarter of 2022, have since been commercialized, also contributing to the increase in the revenue of the Group.
As the Company is still in the process of finalizing the interim results of the Group for the first half of 2023. The above operating information is provided for investors' reference only.
About Peijia Medical Limited
Peijia Medical, headquartered in Suzhou, Jiangsu Province, China, was established in 2012 and listed on the Main Board of the Hong Kong Stock Exchange in May 2020 (Stock Code: 9996. HK). Adhering to the corporate vision of "Dedication with Passion, Devotion for Life", always put life and safety first, cultivate technology deeply, persist in innovation, and do as much as it can for helping life and health. With the strategic layout of "Innovation-oriented, Simultaneous Treatment of Heart and Cerebrovascular Diseases" and focusing on the innovation, R&D and production of high-end medical devices for structural heart and cerebrovascular disease intervention, Peijia Medical covers the entire product pipeline for aortic, mitral and tricuspid valve replacements and surgical instruments and accessories, as well as diseases related to hemorrhagic, ischemic and vascular access in the field of neurointervention, built a relatively comprehensive product portfolio and solutions in the field of structural heart and neurovascular diseases in China.
Topic: Press release summary
Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
Latest Press Releases
OMP Positioned Highest for Both Completeness of Vision and Ability to Execute in the 2026 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions: Process Industries
Mar 23, 2026 23:15 HKT/SGT
|
|
|
Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Mar 23, 2026 21:05 HKT/SGT
|
|
|
Essex Bio-Technology Reports Robust Results for FY2025, Turnover Soars 8.6% to HK$1814 million, Net Profit up 3.5% to HK$ 318.1 million, Total Dividend Increases by 16.7% to HK14 Cents per Share
Mar 23, 2026 20:51 HKT/SGT
|
|
|
GMG Launches European Sales Team; G(R) Lubricant Patent Accepted for Europe
Mar 23, 2026 20:29 HKT/SGT
|
|
|
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint
Mar 23, 2026 18:59 HKT/SGT
|
|
|
From SGD to Global Spending: How Singaporeans Can Avoid FX Fees While Travelling Overseas
Mar 23, 2026 14:15 HKT/SGT
|
|
|
Fujitsu-developed traffic simulation system utilized in Maebashi City's public transportation planning
Monday, March 23, 2026 1:24:00 PM
|
|
|
Hitachi Receives the 2026 Catalyst Award, a Global Recognition for Building an Inclusive Organization
Monday, March 23, 2026 10:49:00 AM
|
|
|
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
Monday, March 23, 2026 10:19:00 AM
|
|
|
Unitree Robotics IPO Ignites Embodied-Intelligence Rally, Shoucheng Holdings (0697.HK) Faces a Dual Catalyst of 'Investment Realisation+Platform Re-Rating'
Mar 23, 2026 08:22 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
